MCID: RTN017
MIFTS: 60

Retinal Detachment

Categories: Eye diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Retinal Detachment

MalaCards integrated aliases for Retinal Detachment:

Name: Retinal Detachment 57 11 28 53 5 41 43 14 16 71 75
Rhegmatogenous Retinal Detachment 33
Ruptured Retina with Detachment 33
Retinal Hole with Detachment 33
Retinal Detachments 14

Characteristics:


Inheritance:

Autosomal dominant 57

Classifications:



External Ids:

Disease Ontology 11 DOID:5327
OMIM® 57 180050
ICD9CM 34 361.9
MeSH 43 D012163
NCIt 49 C26874
SNOMED-CT 68 155103005
ICD10 31 H33.0 H33.2
MedGen 40 C0035305
ICD11 33 2059145710
UMLS 71 C0035305

Summaries for Retinal Detachment

MedlinePlus: 41 The retina is a layer of tissue in the back of your eye that senses light and sends images to your brain. It provides the sharp, central vision needed for reading, driving, and seeing fine detail. A retinal detachment lifts or pulls the retina from its normal position. It can occur at any age, but it is more common in people over age 40. It affects men more than women and whites more than African Americans. A retinal detachment is also more likely to occur in people who: Are extremely nearsighted Have had a retinal detachment in the other eye Have a family history of retinal detachment Have had cataract surgery Have other eye diseases or disorders Have had an eye injury Symptoms include an increase in the number of floaters, which are little "cobwebs" or specks that float about in your field of vision, and/or light flashes in the eye. It may also seem like there is a "curtain" over your field of vision. A retinal detachment is a medical emergency. If not promptly treated, it can cause permanent vision loss. If you have any symptoms, see an eye care professional immediately. Treatment includes different types of surgery. NIH: National Eye Institute

MalaCards based summary: Retinal Detachment, also known as rhegmatogenous retinal detachment, is related to vitreoretinopathy, neovascular inflammatory and persistent hyperplastic primary vitreous, autosomal recessive. An important gene associated with Retinal Detachment is COL2A1 (Collagen Type II Alpha 1 Chain), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Lidocaine and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include retina, eye and brain, and related phenotypes are nervous system and pigmentation

OMIM®: 57 Primary or spontaneous detachment of the retina occurs due to underlying ocular disease and often involves the vitreous as well as the retina. The precipitating event is formation of a retinal tear or hole, which permits fluid to accumulate under the sensory layers of the retina and creates an intraretinal cleavage that destroys the neurosensory process of visual reception. Vitreoretinal degeneration and tear formation are painless phenomena, and in most cases, significant vitreoretinal pathology is found only after detachment of the retina starts to cause loss of vision or visual field. Without surgical intervention, retinal detachment will almost inevitably lead to total blindness (summary by McNiel and McPherson, 1971). (180050) (Updated 24-Oct-2022)

Wikipedia: 75 Retinal detachment is a disorder of the eye in which the retina peels away from its underlying layer of... more...

Related Diseases for Retinal Detachment

Diseases related to Retinal Detachment via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 880)
# Related Disease Score Top Affiliating Genes
1 vitreoretinopathy, neovascular inflammatory 33.0 VEGFA TIMP1 GLUL GFAP
2 persistent hyperplastic primary vitreous, autosomal recessive 32.8 TSPAN12 ATOH7
3 stickler syndrome 32.6 COL9A3 COL2A1 COL11A1
4 kniest dysplasia 32.6 COL9A3 COL2A1 COL11A1
5 exudative vitreoretinopathy 32.5 VEGFA TSPAN12 NDP LRP5 FZD4 CTNNB1
6 vitreoretinopathy 32.4 VEGFA TSPAN12 NDP LRP5 FZD4 CTNNB1
7 macular holes 32.3 VEGFA SERPINF1 RS1
8 vitreoretinal degeneration 32.3 TSPAN12 LRP5
9 spondyloepiphyseal dysplasia congenita 32.3 COL9A3 COL2A1 COL11A1
10 spondyloepimetaphyseal dysplasia, strudwick type 32.2 COL9A3 COL2A1 COL11A1
11 myopia 32.0 VEGFA TIMP1 SERPINF1 RHO COL2A1 COL11A1
12 persistent hyperplastic primary vitreous 32.0 VEGFA TSPAN12 NDP-AS1 NDP LRP5 FZD4
13 vitreous detachment 31.9 VEGFA RS1 GFAP COL11A1
14 coats disease 31.8 VEGFA TSPAN12 RS1 RHO NDP LRP5
15 exudative vitreoretinopathy 2, x-linked 31.7 NDP-AS1 NDP
16 retinal perforation 31.7 VEGFA RS1 RHO COL9A3 COL2A1 COL11A1
17 microvascular complications of diabetes 1 31.7 VEGFA TIMP1 SERPINF1 GFAP
18 retinal degeneration 31.7 SERPINF1 RS1 RHO GFAP COL2A1
19 central serous chorioretinopathy 31.6 VEGFA SERPINF1
20 exudative vitreoretinopathy 1 31.6 VEGFA TSPAN12 SERPINF1 RHO PDGFB NDP
21 strabismus 31.5 TSPAN12 RS1 FZD4 CTNNB1 COL2A1 COL11A1
22 macular retinal edema 31.4 VEGFA SERPINF1 RHO
23 refractive error 31.3 VEGFA RHO COL2A1 COL11A1
24 macular dystrophy, dominant cystoid 31.2 VEGFA RS1 RHO
25 cataract 31.2 VEGFA TIMP1 SERPINF1 RHO CTNNB1 COL2A1
26 microvascular complications of diabetes 5 31.2 VEGFA SERPINF1 RHO PDGFB
27 peripheral retinal degeneration 31.0 TSPAN12 RHO COL2A1
28 vitreous syneresis 31.0 COL9A3 COL2A1 COL11A1
29 central retinal artery occlusion 30.9 VEGFA RS1
30 preretinal fibrosis 30.9 VEGFA GLUL GFAP
31 retinal telangiectasia 30.8 VEGFA TSPAN12 NDP LRP5 FZD4
32 connective tissue disease 30.8 VEGFA TIMP1 CTNNB1 COL9A3 COL2A1 COL11A1
33 brittle bone disorder 30.7 VEGFA SERPINF1 LRP5 CTNNB1 COL2A1 COL11A1
34 macular degeneration, age-related, 1 30.7 VEGFA SERPINF1 RS1 RHO GFAP
35 vitreoretinal dystrophy 30.7 TSPAN12 RS1
36 retinal vascular disease 30.7 VEGFA TSPAN12 SERPINF1 RHO NDP FZD4
37 osteoporosis 30.6 VEGFA NDP LRP5 FZD4 CTNNB1 COL2A1
38 retinal ischemia 30.6 VEGFA RHO GFAP
39 osteoporosis-pseudoglioma syndrome 30.6 NDP LRP5 FZD4 CTNNB1
40 glaucoma, primary open angle 30.5 VEGFA RHO COL11A1 ATOH7
41 chorioretinal scar 30.5 VEGFA RHO
42 leukocoria 30.5 TSPAN12 RS1 NDP-AS1 NDP LRP5 FZD4
43 marshall syndrome 30.4 COL9A3 COL2A1 COL11A1
44 norrie disease 30.4 VEGFA TSPAN12 RS1 NDP-AS1 NDP LRP5
45 multiple epiphyseal dysplasia 30.4 COL9A3 COL2A1 COL11A1
46 eye disease 30.3 VEGFA TSPAN12 TIMP1 SERPINF1 RS1 RHO
47 brain edema 30.2 VEGFA GLUL GFAP
48 choroideremia 30.2 SERPINF1 RS1 RHO
49 retinal vascular occlusion 30.2 VEGFA SERPINF1 RHO
50 retinitis pigmentosa 30.1 VEGFA TSPAN12 TIMP1 SERPINF1 RS1 RHO

Comorbidity relations with Retinal Detachment via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Retinal Detachment:



Diseases related to Retinal Detachment

Symptoms & Phenotypes for Retinal Detachment

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Eyes:
retinal detachment
no myopia

Clinical features from OMIM®:

180050 (Updated 24-Oct-2022)

MGI Mouse Phenotypes related to Retinal Detachment:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.13 ATOH7 COL11A1 COL2A1 COL9A3 CTNNB1 FZD4
2 pigmentation MP:0001186 10.02 ADAMTSL4 CTNNB1 FZD4 LRP5 NDP PDGFB
3 normal MP:0002873 9.97 ATOH7 COL2A1 CTNNB1 FZD4 GFAP GLUL
4 cardiovascular system MP:0005385 9.83 ATOH7 COL11A1 COL2A1 CTNNB1 FZD4 GFAP
5 hearing/vestibular/ear MP:0005377 9.7 COL11A1 COL2A1 COL9A3 CTNNB1 FZD4 NDP
6 vision/eye MP:0005391 9.47 ADAMTSL4 ATOH7 COL2A1 CTNNB1 FZD4 GFAP

Drugs & Therapeutics for Retinal Detachment

Drugs for Retinal Detachment (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 165)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Triazolam Approved, Investigational Phase 4 28911-01-5 5556
5
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
6
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
7
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
8
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
9
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
10
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
11
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
12
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
13
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
14
Bevacizumab Approved, Investigational Phase 4 216974-75-3 135329020
15
Moxifloxacin Approved, Investigational Phase 4 186826-86-8, 354812-41-2, 151096-09-2 152946
16
Atropine Approved, Vet_approved Phase 4 101-31-5, 5908-99-6, 51-55-8 3661 154417 174174
17
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
18
Framycetin Approved, Experimental, Vet_approved Phase 4 1404-04-2, 3947-65-7, 119-04-0 413349 8378
19
Cefazolin Approved Phase 4 25953-19-9 33255
20
Vancomycin Approved Phase 4 1404-90-6 14969
21
Ethinylestradiol Approved Phase 4 57-63-6 5991
22
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
23
Polymyxin B Approved, Vet_approved Phase 4 1405-20-5, 1404-26-8 4868
24
Polyestradiol phosphate Approved Phase 4 28014-46-2
25
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
26
Rasagiline Approved Phase 4 136236-51-6 3052776
27
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
29
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
30 Sodium Channel Blockers Phase 4
31 Diuretics, Potassium Sparing Phase 4
32 Proxymetacaine Phase 4
33 Hypnotics and Sedatives Phase 4
34 Anesthetics, Local Phase 4
35 Adrenergic Agents Phase 4
36 Adrenergic alpha-Agonists Phase 4
37 Adrenergic Agonists Phase 4
38 Immunoglobulins, Intravenous Phase 4
39 Immunoglobulin G Phase 4
40 Anesthetics, Intravenous Phase 4
41 Anesthetics, General Phase 4
42 Anesthetics Phase 4
43 Folic Acid Antagonists Phase 4
44 Folate Phase 4
45 Immunosuppressive Agents Phase 4
46 Vitamin B9 Phase 4
47 Vitamin B Complex Phase 4
48 Immunologic Factors Phase 4
49
Methylprednisolone Acetate Phase 4 584547
50 Antineoplastic Agents, Immunological Phase 4

Interventional clinical trials:

(show top 50) (show all 176)
# Name Status NCT ID Phase Drugs
1 Assessing the Efficacy and Safety of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert, When Placed Within the Lower Eye Lid Canaliculus in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment Unknown status NCT04464629 Phase 4 Dextenza;Prednisolone Acetate
2 Adjunctive Local Application of Lidocaine During Scleral Buckling Under General Anesthesia Unknown status NCT01417572 Phase 4 lidocaine
3 Comparative Analysis of Oral Sedation Versus Standard Intravenous Sedation in Vitreoretinal Surgery With Topical Anesthesia and Sub-tenon's Block Unknown status NCT04346095 Phase 4 Oral Sedatives with or Without Analgesia;Intravenous Sedatives with or Without Analgesia
4 Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
5 On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD. Unknown status NCT01670162 Phase 4 Aflibercept
6 The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery Completed NCT01995045 Phase 4 Triamcinolone;Bupivicaine Hydrochloride
7 Different Conbercept Injection Methods in Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT02816710 Phase 4 Conbercept
8 Comparison of Dexmedetomidine vs. Propofol in Vitreoretinal Surgery Under Sub-Tenon's Block Completed NCT01001429 Phase 4 Dexmedetomidine infusion;propofol
9 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
10 Open Label Study: Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment. Completed NCT01722656 Phase 4 Aflibercept
11 A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration Completed NCT02142296 Phase 4 Eylea
12 Intravitreal Ranibizumab in Patients With Retinal Pigment Epithelial Detachments Secondary to Age-related Macular Degeneration Completed NCT00976222 Phase 4 intravitreal injection with ranibizumab
13 A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD. Completed NCT01628354 Phase 4 Ranibizumab
14 Using Intraoperative Triamcinolone Acetonide Irrigation to Reduce Post-Operative Pain From Scleral Buckle Surgery Recruiting NCT04701593 Phase 4 Triamcinolone Acetonide 40mg/mL
15 Dropless Pars Plana Vitrectomy Study Recruiting NCT05331664 Phase 4 Triamcinolone Acetonide 40mg/mL;Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin;Prednisolone 1%;Atropine 1%
16 Peripheral Retinal Cryoapplication Versus Anti-VEGF Intravitreal Injection Before Vitrectomy for Complicated Proliferative Diabetic Retinopathy Recruiting NCT05514925 Phase 4 Bevacizumab Injection [Avastin]
17 Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment Terminated NCT02068625 Phase 4 Rasagiline;Placebo
18 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Terminated NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
19 Effect of Dexamethasone on Postoperative Symptoms of Scleral Buckling Surgery Patients: a Randomized Control Trial Withdrawn NCT01326585 Phase 4 Dexamethasone Sodium Phosphate Injection;Saline Injection
20 This is an Open Label Study to Evaluate the Efficacy of Intravitreal Aflibercept Injection 2mg in Patients With a Persistent FVPED Despite at Least 6 Consecutive Injections With Ranibizumab 0.5 mg Withdrawn NCT01495208 Phase 4 Aflibercept
21 Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy. Withdrawn NCT01666236 Phase 4
22 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
23 Comparison of Two High-Density Silicone Oils in Complicated Rhegmatogenous Retinal Detachment Unknown status NCT00403702 Phase 2, Phase 3 Oxane HD [oil-RMN3-mixture];Densiron [(F6H8)
24 Pressurized Perfluorocarbon Perfused 23 GA Vitrectomy in Complicated Diabetic Retinal Detachment Unknown status NCT00404209 Phase 3
25 Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Unknown status NCT00370201 Phase 3 colchicine
26 Suprachoroidal Triamcinolone Acetonide Injection A Novel Therapy for Serous Retinal Detachment in Vogt-Koyanagi Harada's Disease Completed NCT05031143 Phase 2, Phase 3 Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease
27 Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy: Results of the Pan-American Collaborative Retina Study (PACORES) Group Completed NCT01976923 Phase 3 Intravitreal bevacizumab
28 Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. Completed NCT02834559 Phase 3 5-fluorouracil and low molecular weight heparin;Placebo
29 Diabetic Retinopathy Vitrectomy Study (DRVS) Completed NCT00000154 Phase 3
30 Comparison of Air and Expansile Gas in Pneumatic Retinopexy Completed NCT00120445 Phase 3
31 Randomized Clinical Trial of Cryotherapy Versus Postoperative Laser Photocoagulation for Retinopexy in Scleral Buckle Surgery Completed NCT01068379 Phase 3
32 The Silicone Study Completed NCT00000140 Phase 3 Perfluoropropane;Sulfur Hexafluoride;Silicone Oil
33 Determining Optimal Treatment Algorithms for Macular Degeneration Pigment Epithelial Detachments Treated With Intraocular Lucentis Completed NCT00590694 Phase 2, Phase 3 ranibizumab
34 A Phase III Randomized 1:1, Masked, Study of the Safety, Tolerability, and Efficacy of Intravitreal Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Adjuvant Management of TRD and Vit Hem Associated With PDR Withdrawn NCT01589718 Phase 3 Macugen;Sham
35 Head Positioning Duration After Retinal Detachment Repair With Vitrectomy and Gas Unknown status NCT03714503 Phase 2
36 Evaluation of Minocycline Neuro Protective Role in Retinal Detachment Surgery Unknown status NCT01297816 Phase 2 placebo;Minocycline
37 Perfluorocarbon Gases for the Repair of Retinal Detachments. Unknown status NCT00161525 Phase 2
38 The Effect of Intravitreous Ranibizumab on Intra-Operative Bleeding During Pars Plana Vitrectomy for Diabetic Traction Retinal Detachment Completed NCT01201161 Phase 2 Ranibizumab
39 Bevacizumab Against Recurrent Retinal Detachment Completed NCT02192970 Phase 2 Bevacizumab
40 Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV for Diabetic Tractional Retinal Detachment (IBETRA Study) Completed NCT00690768 Phase 2 Bevacizumab
41 Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System in Improving Visual Function Completed NCT00972374 Phase 2 400 ug Brimonidine Implant;200 ug Brimonidine Implant
42 Intravitreal Lucentis (iL) (Ranibizumab) for the Treatment of AMD Related Pigment Epithelial Detachment (PED) Completed NCT00841581 Phase 2 Ranibizumab
43 Treatment of Proliferative Vitreoretinopathy With Intravitreal Infliximab Recruiting NCT04891991 Phase 2 Intravitreal infliximab
44 A Multi-Center, Randomized, Sham-Controlled, Phase II Trial Evaluating Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Macula Off Rhegmatogenous Retinal Detachment Repair (The PREVENT-PVR Trial) Recruiting NCT04580147 Phase 2 Intravitreal aflibercept injection
45 Amniotic Membrane Visio-AMTRIX in Recurrent Macular Hole Recruiting NCT05191628 Phase 2
46 Scleral Buckling for Retinal Detachment Prevention in Genetically Confirmed Stickler Syndrome : a Randomized Controlled Trial Not yet recruiting NCT04465188 Phase 2
47 A Prospective Matched Cohort Study of Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment With Proliferative Vitreoretinopathy Not yet recruiting NCT05523869 Phase 2 Intravitreal topotecan
48 A Randomized, Double-Masked, Placebo Controlled, Parallel Group, Multi-Center, Dose-Ranging Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects With Rhegmatogenous Retinal Detachment Terminated NCT00083967 Phase 2 denufosol tetrasodium (INS37217) Intravitreal Injection
49 High Dose Lucentis for Persistent Pigment Epithelial Detachment in Neovascular Age-related Macular Degeneration - The HiPED Study Terminated NCT01189019 Phase 2 ranibizumab
50 The Multi-center Exploratory Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment Unknown status NCT01261533 Phase 1

Search NIH Clinical Center for Retinal Detachment

Cochrane evidence based reviews: retinal detachment

Genetic Tests for Retinal Detachment

Genetic tests related to Retinal Detachment:

# Genetic test Affiliating Genes
1 Retinal Detachment 28

Anatomical Context for Retinal Detachment

Organs/tissues related to Retinal Detachment:

MalaCards : Retina, Eye, Brain, Endothelial, Bone Marrow, Cortex, Lung

Publications for Retinal Detachment

Articles related to Retinal Detachment:

(show top 50) (show all 20888)
# Title Authors PMID Year
1
Localized versus 360-degree laser photocoagulation with limited pars plana vitrectomy in the management of primary rhegmatogenous retinal detachment. 62 41
36207689 2022
2
Risk of retinal detachment and exposure to fluoroquinolones, common antibiotics, and febrile illness using a self-controlled case series study design: Retrospective analyses of three large healthcare databases in the US. 62 41
36201545 2022
3
The burden of flashes and floaters in traditional general emergency services and utilization of ophthalmology on-call consultation: a cross-sectional study. 41
36195837 2022
4
Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment. 53 62
20465445 2010
5
Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. 53 62
19643496 2009
6
The effects of transient retinal detachment on cavity size and glial and neural remodeling in a mouse model of X-linked retinoschisis. 53 62
19387072 2009
7
Resolution of persistent exudative retinal detachment in a case of Sturge-Weber syndrome with anti-VEGF administration. 53 62
19657986 2009
8
Upregulation of Semaphorin 3A and the associated biochemical and cellular events in a rat model of retinal detachment. 53 62
18815803 2009
9
Correlation of the extent and duration of rhegmatogenous retinal detachment with the expression of matrix metalloproteinases in the vitreous. 53 62
18046238 2007
10
Treatment of total exudative retinal detachment due to central retinal vein occlusion by intravitreal bevacizumab in a patient with p-ANCA vasculitis. 53 62
19668494 2007
11
Expression of matrix metalloproteinases in the subretinal fluid correlates with the extent of rhegmatogenous retinal detachment. 53 62
16941143 2007
12
[What can we learn from molecular genetic analyses of inherited eye diseases?]. 53 62
17134037 2006
13
Detection of PEDF in subretinal fluid of retinal detachment: possible role in the prevention of subretinal neovascularization. preliminary results. 53 62
16679806 2006
14
Intraretinal immunohistochemistry findings in proliferative vitreoretinopathy with retinal shortening. 53 62
16679807 2006
15
Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. 53 62
15635051 2005
16
A novel mutation of COL2A1 resulting in dominantly inherited rhegmatogenous retinal detachment. 53 62
15671297 2005
17
High TGF-beta2 levels during primary retinal detachment may protect against proliferative vitreoretinopathy. 53 62
15505063 2004
18
A case of Kniest dysplasia with retinal detachment and the mutation analysis. 53 62
14644246 2003
19
Frizzled 4 gene (FZD4) mutations in patients with familial exudative vitreoretinopathy with variable expressivity. 53 62
14507768 2003
20
Autosomal dominant rhegmatogenous retinal detachment associated with an Arg453Ter mutation in the COL2A1 gene. 53 62
12939326 2003
21
Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF). 53 62
12845559 2003
22
Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. 53 62
12670875 2003
23
Up-regulation of glial fibrillary acidic protein in response to retinal injury: its potential role in glial remodeling and a comparison to vimentin expression. 53 62
14692684 2003
24
A feasible tool to detect mRNA expression of matrix metalloproteinases and their tissue inhibitors in human Tenon's capsule. 53 62
12483026 2002
25
Vitreoretinopathy with phalangeal epiphyseal dysplasia, a type II collagenopathy resulting from a novel mutation in the C-propeptide region of the molecule. 53 62
12205109 2002
26
Basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in vitreous fluid from eyes with retinal detachment complicated by proliferative vitreoretinopathy. 53 62
12208248 2002
27
Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. 53 62
11914216 2002
28
Levels of basic fibroblast growth factor, glutamine synthetase, and interleukin-6 in subretinal fluid from patients with retinal detachment. 53 62
11589877 2001
29
Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy. 53 62
11264138 2001
30
Concentration of vascular endothelial growth factor in the subretinal fluid of retinal detachment. 53 62
11110038 2000
31
Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. 53 62
10980138 2000
32
Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. 53 62
11148602 2000
33
Fibrinolytic activity of subretinal fluid after cryopexy. 53 62
10651193 1999
34
Elevated vascular endothelial growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. 53 62
12579655 1999
35
Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. 53 62
10067974 1999
36
Predominance of MMP-1 and MMP-2 in epiretinal and subretinal membranes of proliferative vitreoretinopathy. 53 62
9986746 1999
37
TIMP-1 and TIMP-2 levels in vitreous and subretinal fluid. 53 62
9822966 1998
38
Ocular complications and a new surgical approach to lens dislocation in homocystinuria due to cystathionine-beta-synthetase deficiency. 53 62
9587034 1998
39
Vascular endothelial growth factor upregulation in human central retinal vein occlusion. 53 62
9499769 1998
40
[Concentration of vascular endothelial growth factor within the subretinal space and vitreous fluid in rhegmatogenous retinal detachment]. 53 62
9209137 1997
41
[Biological activity of subretinal fluid in selected in vitro tests]. 53 62
9685781 1997
42
Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor. 53 62
7485392 1995
43
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. 53 62
7540233 1995
44
Glial fibrillary acidic protein and its mRNA: ultrastructural detection and determination of changes after CNS injury. 53 62
1486005 1992
45
Cytokines in proliferative vitreoretinopathy. 53 62
1800167 1991
46
Efficacy and Safety of Pars Plana Vitrectomy for Primary Symptomatic Floaters: A Systematic Review with Meta-Analyses. 62
36198880 2022
47
Pseudo second anterior lens capsule during post-vitrectomy cataract surgery: A case report. 62
36111278 2022
48
Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity. 62
34711941 2022
49
A tale of orbital cellulitis and retinopathy of prematurity in an infant: First case report. 62
34137305 2022
50
PREVALENCE, CHARACTERISTICS, AND OUTCOMES OF RHEGMATOGENOUS RETINAL DETACHMENT IN EYES WITH TRABECULECTOMY OR GLAUCOMA DRAINAGE DEVICES. 62
35963003 2022

Variations for Retinal Detachment

ClinVar genetic disease variations for Retinal Detachment:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RHO NM_000539.3(RHO):c.891C>G (p.Ser297Arg) SNV Pathogenic
523376 rs142285818 GRCh37: 3:129251570-129251570
GRCh38: 3:129532727-129532727
2 COL2A1 NM_001844.5(COL2A1):c.842_843insT (p.Gly282fs) INSERT Pathogenic
812293 rs1592230091 GRCh37: 12:48387804-48387805
GRCh38: 12:47994021-47994022
3 COL9A3 NM_001853.4(COL9A3):c.1107+1G>C SNV Likely Pathogenic
973782 rs1384292566 GRCh37: 20:61461034-61461034
GRCh38: 20:62829682-62829682
4 COL9A3 NM_001853.4(COL9A3):c.388G>A (p.Gly130Ser) SNV Likely Pathogenic
392918 rs139401633 GRCh37: 20:61453127-61453127
GRCh38: 20:62821775-62821775
5 NDP-AS1, NDP NM_000266.4(NDP):c.308_311dup (p.Lys104fs) DUP Likely Pathogenic
523342 rs1555976049 GRCh37: X:43809135-43809136
GRCh38: X:43949889-43949890
6 EYS NM_001142800.2(EYS):c.4152del (p.Pro1385fs) DEL Uncertain Significance
523414 rs1185686653 GRCh37: 6:65301608-65301608
GRCh38: 6:64591715-64591715

Expression for Retinal Detachment

Search GEO for disease gene expression data for Retinal Detachment.

Pathways for Retinal Detachment

Pathways related to Retinal Detachment according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.63 VEGFA TIMP1 PDGFB LRP5 FZD4 CTNNB1
2 13.27 VEGFA RHO PDGFB LRP5 GFAP FZD4
3
Show member pathways
12.8 VEGFA PDGFB COL9A3 COL2A1 COL11A1
4
Show member pathways
12.52 COL11A1 COL2A1 COL9A3 PDGFB TIMP1
5
Show member pathways
12.44 TIMP1 RS1 PDGFB CTNNB1
6 12.41 VEGFA SERPINF1 PDGFB LRP5 CTNNB1
7
Show member pathways
12.28 CTNNB1 FZD4 LRP5 PDGFB
8 12.05 VEGFA PDGFB CTNNB1 COL2A1
9
Show member pathways
11.89 PDGFB CTNNB1 COL2A1 COL11A1
10 11.88 VEGFA PDGFB GFAP CTNNB1 COL9A3 COL2A1
11
Show member pathways
11.84 LRP5 FZD4 CTNNB1
12 11.84 VEGFA LRP5 FZD4 CTNNB1
13 11.76 GFAP CTNNB1 COL2A1
14 11.72 VEGFA TIMP1 FZD4
15
Show member pathways
11.65 PDGFB COL9A3 COL2A1
16 11.6 VEGFA PDGFB GFAP
18 11.36 VEGFA COL2A1 COL11A1
19 11.08 CTNNB1 PDGFB VEGFA
20 10.76 VEGFA PDGFB
21 10.71 VEGFA PDGFB
22 10.34 TIMP1 PDGFB GFAP COL9A3 COL2A1 COL11A1

GO Terms for Retinal Detachment

Cellular components related to Retinal Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.4 VEGFA TIMP1 SERPINF1 RS1 PDGFB NDP
2 endoplasmic reticulum lumen GO:0005788 9.93 ADAMTSL4 COL11A1 COL2A1 COL9A3 PDGFB TIMP1
3 basement membrane GO:0005604 9.92 TIMP1 SERPINF1 COL9A3 COL2A1
4 collagen-containing extracellular matrix GO:0062023 9.8 SERPINF1 PDGFB NDP COL9A3 COL2A1 COL11A1
5 collagen type XI trimer GO:0005592 9.67 COL11A1 COL2A1
6 collagen trimer GO:0005581 9.65 TIMP1 COL9A3 COL2A1 COL11A1
7 extracellular matrix GO:0031012 9.44 VEGFA TIMP1 NDP COL9A3 COL2A1 COL11A1

Biological processes related to Retinal Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 visual perception GO:0007601 10.02 COL11A1 COL2A1 NDP RHO RS1
2 positive regulation of DNA-binding transcription factor activity GO:0051091 10.01 NDP LRP5 FZD4 CTNNB1
3 extracellular matrix organization GO:0030198 9.96 GFAP COL9A3 COL2A1 COL11A1 ADAMTSL4
4 heart morphogenesis GO:0003007 9.85 VEGFA COL2A1 COL11A1
5 epithelial cell proliferation involved in prostate gland development GO:0060767 9.78 SERPINF1 CTNNB1
6 retinal blood vessel morphogenesis GO:0061304 9.73 LRP5 FZD4
7 positive regulation of retinal ganglion cell axon guidance GO:1902336 9.67 VEGFA ATOH7
8 retina vasculature morphogenesis in camera-type eye GO:0061299 9.55 NDP LRP5 FZD4
9 extracellular matrix-cell signaling GO:0035426 9.43 NDP LRP5 FZD4
10 Norrin signaling pathway GO:0110135 9.1 NDP LRP5 FZD4

Molecular functions related to Retinal Detachment according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix structural constituent conferring tensile strength GO:0030020 9.43 COL9A3 COL2A1 COL11A1
2 Wnt receptor activity GO:0042813 9.02 TSPAN12 LRP5 FZD4

Sources for Retinal Detachment

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....